Here are the 2025 dividend forecasts for FTSE giants Unilever, GSK, and AstraZeneca

These FTSE shares don’t have the highest yields. But Edward Sheldon believes they could deliver attractive returns in the years ahead.

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN), Unilever (LSE: ULVR), and GSK (LSE: GSK) are some of the largest businesses in the FTSE 100. All are blue-chip companies that are popular with investors.

Wondering what kind of dividends they’re likely to serve up in the year ahead? Here’s a look at the dividend forecasts for 2025.

Ignore the low yield

Let’s start with pharmaceutical company AstraZeneca. Because it’s the largest business in the Footsie with a market cap of around £182bn.

Now, the dividend yield here isn’t high. Currently, analysts expect a payout of 327 cents for 2025 – a yield of 2% at today’s share price and at the GBP/USD exchange rate.

But I wouldn’t look at this low yield as a deal-breaker. This company has a brilliant track record when it comes to generating wealth for investors.

Looking ahead, I see potential for more attractive returns. Today, the company has a vast drug pipeline (189 projects) that includes oral weight-loss drugs (which I think could be huge if they come to market).

Of course, pharma companies face plenty of risks. Patent expiration and disappointing drug trial results are two that come to mind.

With the stock trading 10% off its highs on a forward-looking price-to-earnings (P/E) ratio of 16.5, however, I like the set-up today.

Returns of 10% a year

Moving on to consumer goods company Unilever, it’s forecast to pay out 190 euro cents for 2025. At today’s share price, that estimate equates to a yield of 3.3%.

This is another company with a magnificent track record when it comes to generating wealth for investors. Over the last decade, it has returned about 10% per year when dividends are factored in.

I wouldn’t be surprised to see similar kinds of returns from it over the next decade (despite the fact that the P/E ratio is elevated at 20). With plenty of exposure to the fast-growing Indian market, and a new management team driving efficiency gains, I see scope for decent revenue and earnings growth in the years ahead.

It’s worth noting that changing consumer preferences are a risk here. Today, the consumer goods market is evolving rapidly and new brands are capturing market share.

I’m backing Unilever’s trusted brands such as Dove and Hellmann’s – which have been around for decades – to remain popular with consumers, however.

A cheap stock

Finally, we have pharma company GSK. It’s forecast to pay out 64p for 2025. At today’s share price, we’re looking at a yield of around 4.3% – the highest of the three stocks.

Now, this stock is well below its highs at present. That’s because the company has been fighting a battle in relation to its heartburn drug Zantac (which some people claim causes cancer).

However, earlier this month, GSK settled 80,000 Zantac litigation cases (93% of total cases) for around $2.2bn. That clears up a lot of the uncertainty.

Of course, there’s still a bit of uncertainty linked to Zantac. But I like the risk/reward proposition now.

Currently, GSK has a P/E ratio of just 8.6 using the 2025 earnings forecast. That’s a low valuation (well below the healthcare sector average).

There are no guarantees that the stock will do well from here, of course. But at that valuation, I think it’s worth a closer look.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has positions in Unilever. The Motley Fool UK has recommended AstraZeneca Plc, GSK, and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Dividend Shares

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

With yields over 8.8%, which of the FTSE 100’s top 5 passive income stocks do I think is the best?

These five passive income stocks are all yielding more than 8.8%. Our writer considers which of them (if any) would…

Read more »

Dividend Shares

Here’s a simple 5-stock dividend income portfolio with a 7.5% yield

With these five British dividend stocks, one could potentially generate income of around £750 per year from a £10,000 investment.

Read more »

Investing Articles

If I’d put £10,000 into the FTSE 100’s biggest stock at the start of 2024, here’s what I’d have now

The FTSE 100’s biggest company has romped away from the index over the last five years, but has fallen behind…

Read more »

Investing Articles

How I’d use £10 a day to build a lifetime of passive income

Zaven Boyrazian explains his three-step plan to help generate a passive income in 2024 by putting aside just £10 a…

Read more »